About the project
About Pharmacy BPC-157
An independent editorial digest of the peer-reviewed BPC-157 research record. We summarize studies; we do not treat, prescribe, or sell.
What this site is
Pharmacy BPC-157 is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built like an instrument readout because the BPC-157 evidence has a shape worth showing precisely: a deep, decades-long preclinical base — cytoprotection, transected-tendon healing, muscle-crush recovery, the VEGFR2-Akt-eNOS angiogenesis mechanism, the 2022 pharmacokinetics — and a thin top layer of three small human pilots. We print each finding on the layer it belongs to so the gap between the animal base and the human top is never blurred.
Why "Pharmacy" is in the name
The word pharmacy in this domain is editorial framing, not a description of a service. It marks the position this publisher takes toward the literature: a measured, access-aware reading that includes where compounded access of this substance class actually stands — the FDA 503A status, the regulatory pathway, the World Anti-Doping Agency prohibition. It is not a claim that the site is a pharmacy, dispenses anything, or fills prescriptions. It does none of those things.
We do not name vendors, clinics, or telehealth providers, and we do not tell anyone how to obtain BPC-157. The negative-space here is deliberate: this is a research digest, not a storefront.
How we handle citations
Every quantitative claim on the site — every dose, percentage, half-life, and sample size — links to a numbered source on the study references and citations page. Preclinical findings carry a PubMed identifier and, where available, a DOI. The regulatory facts are drawn from a single audited set of FDA pages and stated present-tense, with future FDA action never presented as a certainty.
We distinguish what the literature supports from what it does not. Where popular claims — muscle building, weight loss, raised testosterone — run ahead of the evidence, we say so. Where the human data is thin, we say that too. The aim is a record a careful reader can trust and verify.